LUNG TRANSPLANTATION 2012 דר ' לקסר אורי מכון הראה בית החולים האוניברסיטאי הדסה.

Slides:



Advertisements
Similar presentations
HEART-LUNG TRANSPLANTATION Overall ISHLT 2006 J Heart Lung Transplant 2006;25:
Advertisements

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2006 J Heart Lung Transplant 2006;25:
HEART-LUNG TRANSPLANTATION Overall ISHLT 2005 J Heart Lung Transplant 2005;24:
HEART TRANSPLANTATION Overall ISHLT 2008 J Heart Lung Transplant 2008;27:
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2006 J Heart Lung Transplant 2006;25:
2004 ISHLT J Heart Lung Transplant 2004; 23: HEART TRANSPLANTATION Pediatric Recipients.
2002 ISHLT J Heart Lung Transplant 2002; 21: HEART-LUNG TRANSPLANTATION Overall.
2004 ISHLT J Heart Lung Transplant 2004; 23: HEART-LUNG TRANSPLANTATION Overall.
J Heart Lung Transplant 2009;28: HEART TRANSPLANTATION Pediatric Recipients ISHLT 2009.
HEART-LUNG TRANSPLANTATION
2003 ISHLT J Heart Lung Transplant 2003; 22: HEART TRANSPLANTATION Pediatric Recipients.
2003 ISHLT J Heart Lung Transplant 2003; 22: HEART-LUNG TRANSPLANTATION Overall.
LUNG TRANSPLANTATION Pediatric Recipients 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):
HEART-LUNG TRANSPLANTATION Overall ISHLT 2008 J Heart Lung Transplant 2008;27:
HEART TRANSPLANTATION Pediatric Recipients 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):
HEART-LUNG TRANSPLANTATION Overall 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26:
HEART-LUNG TRANSPLANTATION
LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26.
HEART-LUNG TRANSPLANTATION
LUNG TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):
HEART-LUNG TRANSPLANTATION Overall 2014 JHLT Oct; 33(10):
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
Advances in Lung Transplantation: A Patient Guide David J. Lederer, M.D., M.S. Assistant Professor of Medicine New York Presbyterian Lung Transplant Program.
Extracorporeal Membrane Oxygenation Following Lung Transplantation in Adult ISKANDER AL-GITHMI, M.D., FRCSC, FRCSC (Ts & CDs), FCCP. Assistant Professor.
LUNG TRANSPLANTATION ISKANDER AL-GITHMI, M.D., FRCSC, FRCSC (Ts & CDs), FCCP. Assistant Professor of Surgery Division of Cardiothoracic Surgery King Abdulaziz.
IDIOPATHIC PULMONARY FIBROSIS
LUNG TRANSPLANTATION and PULMONARY FIBROSIS Maria L. Padilla, MD Associate Prof. of Medicine Director of ILD/IPF and Advanced Lung Disease Program MSSM/MSMC.
HEART TRANSPLANTATION Overall ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
Optimizing lung transplant outcomes in the adult and pediatric patient. Cynthia S. Herrington, MD Associate Professor of Surgery Keck School of Medicine.
Overview of Lung Transplantation
HEART-LUNG TRANSPLANTATION Overall ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
LUNG TRANSPLANTATION CURRENT STATUS Iskander Al-Githmi, MD, FRCSC-GS, FRCSC -Ts, FRCSC-CDs, FACS, FCCP Division of Cardiothoracic Surgery King Abdulaziz.
SSA Hearing on Compassionate Allowances Janet N Scheel MD November 9,2010.
CM-1 Clinical Transplantation Lung Howard University Hospital Department of Transplantation Clive O. Callender, MD. Arturo Hernandez, MD.
An International Case Study of Lung Transplantation
BWGHF Liège Heart transplantation 2008.
Lung Transplantation Guidelines For Selection Milpark Hospital Transplant Unit Johannesburg, South Africa SATS Controversies Meeting May 2011.
LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
LUNG TRANSPLANT 1Dr.yekehfallah- phd of nursing /18/2015.
HEART TRANSPLANTATION Pediatric Recipients JHLT Oct; 32(10):
Update on Pediatric Cardiac Transplantation Dr Jameel Al-ata Consultant & Assistant Professor of Pediatrics & Pediatric Cardiology Taif April 2007.
CF Incidence, Prevalence and Survival Carrier rate of 1 in 25 Incidence of 1 in 2,500 live births By 2002 the number.
Lung Transplantation Biology
Surgical outcome of native valve infective endocarditis in srinagarind hospital
Exercise Testing – clinical utility Sudhir Rao Respiratory registrar.
HEART-LUNG TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):
HEART TRANSPLANTATION Pediatric Recipients 2014 JHLT Oct; 33(10):
Is the failure of pulmonary gas exchange to maintain the normal arterial O2 and CO2 level. It is divided in to type I and II in relation to the presence.
LUNG TRANSPLANTATION Adult Recipients 2014 JHLT Oct; 33(10):
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
HEART-LUNG TRANSPLANTATION Pediatric Recipients 2015 JHLT Oct; 34(10):
BTS/ICS Guidelines for the ventilatory management of acute hypercapnic respiratory failure in adults British Thoracic Society Intensive Care Society.
R1 정수웅.  Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause that occurs.
Restrictive lung disease
Dr Julius Cairn. Introduction - update COPD Exacerbations Pulmonary rehabilitation Lung cancer - NSCLC Treatments for patients with limited lung function.
CM-1 Current Status of Lung Transplantation Jeff Golden, MD Professor of Clinical Medicine and Surgery Medical Director, Lung Transplantation University.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL R2 이윤정 Richard A. Belkin, Noreen R. Henig, Lianne G. Singer, Cecilia Chaparro,
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient [ CHEST JULY 2015 ] 호흡기내과 R4. 박세정.
The Registry of the International Society for Heart and Lung Transplantation: Thirty- second Official Adult Lung and Heart-Lung Transplantation Report—2015;
11/11/16 Kirstie Wallace/Hazel Muse Transplant Co-ordinators
COPD Dr MAMATHA SARTHI GPST3.
Effect of volume reduction on lung transplant timing and selection for chronic obstructive pulmonary disease  Joseph E. Bavaria, MD, Alberto Pochettino,
LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2010
LUNG TRANSPLANTATION CURRENT STATUS
HEART-LUNG TRANSPLANTATION
THE AUSTRALIA AND NEW ZEALAND CARDIOTHORACIC ORGAN TRANSPLANT REGISTRY
HEART-LUNG TRANSPLANTATION
HEART TRANSPLANTATION
HEART-LUNG TRANSPLANTATION
Presentation transcript:

LUNG TRANSPLANTATION 2012 דר ' לקסר אורי מכון הראה בית החולים האוניברסיטאי הדסה

INDICATION Lung transplantation is indicated for patients with chronic, end-stage lung disease who are failing maximal medical therapy, or for whom no effective medical therapy exists. COPD IPF PPH CF. The Journal of Heart and Lung Transplantation July 2006

Ideally, listing for transplantation should occur when life expectancy is greatly reduced but nonetheless greater than the expected waiting time for a suitable organ, and transplantation should be performed when life expectancy after transplantation exceeds life expectancy without the procedure. TIMING The Journal of Heart and Lung Transplantation July 2006

AIMS  Survival benefit  Quality of life  Palliation

Absolute contraindications Malignancy in the last 2 years.. Untreatable advanced dysfunction of another major organ system. Non-curable chronic extrapulmonary infection including HBV HCV HIV. Significant chest wall/spinal deformity.. Documented nonadherence. Untreatable psychiatric or psychologic condition. Absence of a consistent or reliable social support. Substance addiction (e.g., alcohol, tobacco, or narcotics) The Journal of Heart and Lung Transplantation July 2006

Relative contraindications Age >65y Unstable condition Limited functional condition 18 >bmi>30 Colonization with resistant organism Ventilation Osteoporosis IHD,D.M.,GERD,HTN …. The Journal of Heart and Lung Transplantation July 2006

COPD Guidelines for Referral. BODE index exceeding 5 Guidelines for Transplantation. Patients with a BODE index* of 7 to 10 or at least 1 of the following:. History of hospitalization for exacerbation associated with acute hypercapnia (PCO2 exceeding 50 mm Hg). Pulmonary hypertension or cor pulmonale, or both, despite oxygen therapy.. FEV1 of less than 20% and either DLCO of less than 20% or homogenous distribution of emphysema. The Journal of Heart and Lung Transplantation July 2006

Cystic fibrosis and bronchiectasis Guidelines for Referral. FEV1 below 30% predicted or a rapid decline in FEV1.. Exacerbation of pulmonary disease requiring ICU stay.. Increasing frequency of exacerbations requiring antibiotic therapy.. Refractory and/or recurrent pneumothorax.. Recurrent hemoptysis not controlled by embolization. Guideline for Transplantation. Oxygen-dependent respiratory failure.. Hypercapnia.. Pulmonary hypertension. The Journal of Heart and Lung TransplantationJuly 2006

PULMONARY FIBROSIS Guideline for Referral early,do not wait to treatment. Histologic or radiographic evidence of UIP irrespective of vital capacity.. Histologic evidence of fibrotic NSIP. Guideline for Transplantation. Histologic or radiographic evidence of UIP and any of the following:. A DLCO of less than 39% predicted.. A 10% or greater decrement in FVC during 6 months of follow-up.. A decrease in pulse oximetry below 88% during 6-MWT.. Honeycombing on HRCT (fibrosis score of 2).. Histologic evidence of NSIP and any of the following:. A DLCO of less than 35% predicted.. A 10% or greater decrement in FVC or 15% decrease in DLCO during 6 months of follow-up. The Journal of Heart and Lung Transplantation July 2006

PULMONARY ARTERIAL HYPERTENSION Guideline for Referral. NYHA functional class III or IV, irrespective of ongoing therapy.. Rapidly progressive disease. Guideline for Transplantation. Persistent NYHA class III or IV on maximal medical therapy.. Low (350 meter) or declining 6-MWT.. Failing therapy with intravenous epoprostenol, or equivalent.. Cardiac index of less than 2 liters/min/m2.. Right atrial pressure exceeding 15 mm Hg. The Journal of Heart and Lung Transplantation July 2006

NUMBER OF LUNG TRANSPLANTS REPORTED BY YEAR AND PROCEDURE TYPE ISHLT NOTE: This figure includes only the lung transplants that are reported to the ISHLT Transplant Registry. As such, this should not be construed as representing changes in the number of lung transplants performed worldwide. 2009

LUNG TRANSPLANTS: Transplant Recipient Age by Year of Transplant Transplants: January 1, 1987 – June 30, 2008 ISHLT 2009

AGE DISTRIBUTION OF LUNG TRANSPLANT RECIPIENTS (1/1985-6/2008) ISHLT 2009

DONOR AGE DISTRIBUTION FOR LUNG TRANSPLANTS (1/1985-6/2008) ISHLT 2009

ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival (Transplants: January June 2007) ISHLT 2009

ADULT LUNG TRANSPLANTATION: Indications for Single Lung Transplants (Transplants: January June 2008) ISHLT *Other includes: Sarcoidosis: 2.1% Bronchiectasis: 0.4% Congenital Heart Disease: 0.2% LAM: 0.8% OB (non-ReTx): 0.5% Miscellaneous:6.3% 2009

ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type (Transplants: January 1990 – June 2007) Diagnosis: Emphysema/COPD ISHLT 2009

ADULT LUNG TRANSPLANTS (1/1995-6/2007) Risk Factors for 1 Year Mortality Recipient Age ISHLT 2009

ADULT LUNG RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: April 1994 – June 2008) ISHLT 2009

ADULT LUNG RECIPIENTS Employment Status of Surviving Recipients (Follow-ups: April 1994 – June 2008) ISHLT 2009

ADULT LUNG RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up For follow-ups between January 2002 through June 2008 Analysis limited to patients receiving prednisone ISHLT Analysis is limited to patients who were alive at the time of the follow-up 2009

POST-LUNG TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 10 Years Post-Transplant (Follow-ups: April June 2008) ISHLT 2009

FREEDOM FROM BRONCHIOLITIS OBLITERANS SYNDROME For Adult Lung Recipients (Follow-ups: April 1994-June 2008) Conditional on Survival to 14 days ISHLT 2009

FREEDOM FROM SEVERE RENAL DYSFUNCTION* For Adult Lung Recipients (Follow-ups: April 1994-June 2008) ISHLT 2009

FREEDOM FROM MALIGNANCY For Adult Lung Recipients (Follow-ups: April 1994-June 2008) ISHLT 2009

ADULT LUNG TRANSPLANT RECIPIENTS: Relative Incidence of Leading Causes of Death (Deaths: January June 2008) ISHLT 2009

מה קורה בישראל ? רשימה ארצית לפי LAS SCORE- : שקלול חומרת המחלה וסכויי הצלחת ההשתלה 11 פרמטרים המרכיבים את הנקוד - תפקודי ראה, מחלות רקע, מחלת היסוד, מצב תפקודי וכ ' תרומה מתורם עם מוות מוחי מוכרז אין תרומה מהחי אין STATUS ONE ריאה מאופיינת בזמן איסכמיה קצר 4-6 שעות זמן המתנה עד שנה לערך - 70 חולים על הרשימה אין שיתוף פעולה אזורי או בינלאומי

תודה